In critically ill patients with COVID-19, antiplatelet therapy did not increase organ support-free days at 21 d

Janhavi Athale; Robert L Danner

doi:10.7326/J22-0046

In critically ill patients with COVID-19, antiplatelet therapy did not increase organ support-free days at 21 d

Ann Intern Med. 2022 Jul;175(7):JC80. doi: 10.7326/J22-0046. Epub 2022 Jul 5.

Authors

Janhavi Athale¹, Robert L Danner²

Affiliations

¹ Mayo Clinic Arizona, Phoenix, Arizona, USA (J.A.).
² National Institutes of Health, Bethesda, Maryland, USA (R.L.D.).

PMID: 35785539
DOI: 10.7326/J22-0046

Abstract

REMAP-CAP Writing Committee for the REMAP-CAP Investigators. Effect of antiplatelet therapy on survival and organ support-free days in critically ill patients with COVID-19: a randomized clinical trial. JAMA. 2022;327:1247-59. 35315874.

Publication types

Randomized Controlled Trial
Comment

MeSH terms

COVID-19*
Critical Illness / therapy
Humans
Platelet Aggregation Inhibitors / therapeutic use
Respiration, Artificial
SARS-CoV-2

Substances

Platelet Aggregation Inhibitors